Stock in Swiss drug company Novartis (NOVN.VX)(NVS.N) is poised to rise as the company's pipeline of new drugs is one of the most promising in the industry.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
Novartis has a $1 billion contract to provide the U.S. government with swine flu (H1N1) vaccine this year. Also two meningitis vaccines should hit the U.S. market by 2012.
Vaccines and biologics, which use proteins rather than chemicals, account for one-quarter of Novartis' pipeline and sales are expected to rise 20 percent annually for the next five year.
It noted Novartis' U.S.-listed stock -- American Depository Receipts -- has risen 33 percent off a seven-year low in March. But shares have lagged behind the broader stock market gains, mostly because foreign currency fluctuations hurt revenue.
StockEinstein.com has a dedicated team uncovering stocks ready to break and run. We apply time tested criteria and when one of these stocks meets or exceeds our benchmarks, our subscribers are immediately notified directly to their in-box.
This is a free service available only to our subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.
During 2009 our alerts have resulted in an average price gain of 80%+.
Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
